Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab plus talazoparib in BRCA1/2- or ATM-mutant advanced solid tumors
NL-OMON48840Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- May 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab and talazoparib in Nonhematologic neoplasms, ovarian cancer, breast cancer and 2 more, sponsored by Pfizer. Primary endpoint: Confirmed objective response. Started May 2019; status: active, not recruiting.
02
Drugs
avelumabtalazoparib
03
Conditions
Nonhematologic neoplasmsovarian cancerbreast cancerprostate cancer (PCa)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON48840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48840.